RADICAVA ORS® (edaravone)

The Wholesale Acquisition Cost* of RADICAVA ORS® Starter Kit (14 doses) (NDC 70510-2321-2) is $20,146.53, and RADICAVA ORS® maintenance kit (10 doses) (NDC 70510-2322-1) is $14,390.38.

*Please note that the WAC reflects the list price for the drug to wholesalers in the United States as of 03/01/2025 and does not reflect any discounts, rebates, or other reductions in price.

Your patients’ out-of-pocket cost may be different.

Medi-Span Price Rx. Medi-Span: Drug data solutions for healthcare. Accessed March 1, 2025.

IMPORTANT SAFETY
INFORMATION

Hypersensitivity Reactions

RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.

Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.

Adverse Reactions

The most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.

Pregnancy

Based on animal data, RADICAVA ORS may cause fetal harm.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Please see the full Prescribing Information, also available www.radicavaors.com.